Device Trial Radar · NCT07632001
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Mar 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Reprise Biomedical, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate whether the Miro3D Wound Matrix, when used in addition to standard of care, improves healing outcomes in patients with chronic diabetic foot ulcers. Diabetic foot ulcers are a common and serious complication of diabetes and may be difficult to heal despite appropriate treatment. Standard of care typically includes regular wound cleaning, debridement (removal of dead tissue), offloading (reducing pressure on the wound), and moisture-balancing dressings. However, some wounds fail to heal with standard treatment alone. Miro3D Wound Matrix is a three-dimensional, acellular scaffold derived from porcine tissue that is intended to support wound healing. This study will compare outcomes in patients treated with Miro3D plus standard of care versus standard of care alone. Approximately 180 adult subjects with non-healing diabetic foot ulcers will be enrolled at multiple clinical sites in the United States. After a two-week screening period, eligible participants will be randomly assigned to receive either Miro3D in addition to standard of care or standard of care alone. Subjects will be followed for up to 12 weeks with weekly clinic visits. The primary objective of the study is to determine whether treatment with Miro3D increases the rate of complete wound closure and improves reduction in wound size compared to standard of care alone. Safety will also be evaluated by monitoring adverse events throughout the study.
Conditions
- Diabetic Foot Ulcers (DFUs)
- Diabetic Foot
- Chronic Wounds
Interventions
Miro3D Wound MatrixDevice
Miro3D Wound Matrix is a sterile, acellular, three-dimensional scaffold derived from porcine liver tissue and applied topically to the wound following appropriate wound bed preparation to support tissue regeneration and healing.
Standard of CareOther
Standard of care includes sharp debridement, offloading using a protocol-defined device, and appropriate moisture-retentive dressings.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving Complete Wound Closure of the Target Diabetic Foot Ulcer at 12 WeeksTime frame: Up to 12 weeks
- Mean Percentage Reduction in Target Ulcer Surface Area From Baseline to 12 WeeksTime frame: Baseline through 12 weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Advanced Foot Care
Phoenix, Arizona · Recruiting
West Boca Center for Wound Healing
Coconut Creek, Florida · Not yet recruiting
Solutions Medical Research
Coral Gables, Florida · Recruiting
11 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.